News and updates — Page 24 of 28 — German Market Access

Three new methods were added to the catalogue of SHI funds

Before a new diagnostic and treatment method can be offered and reimbursed in the outpatient sector, two important steps need to be

Registry-based RCT could provide important answers on the optimal treatments and their sequencing for RRMS, but a lack of reimbursement hinders these

After several years of discussions, the EU will start to conduct joint HTAs in 2024. This process will be organized and overseen

In the recent early benefit assessment of nivolumab, the G-BA not only accepted the submitted ITC, but this also resulted in a

The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It